Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory Disease, Neurodegeneration, and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for p38 Alpha drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | p38 Alpha Active & Inactive Recombinant Kinase. High purity (>95%), Endotoxin <1EU/ug. Sf9 expressed, Sequence Verified. Includes T106M gatekeeper mutant proteins for resistance profiling. | View MAPK14 Products |
| Gene Delivery | MAPK14 Promise-ORF / Lentivirus. Full-length ORF for stable cell lines and cellular kinase assays. | View MAPK14 Products |
| Benchmark Ab | Anti-p38 Alpha (Total & Phospho-T180/Y182). Recombinant positive control antibodies for pathway activation detection. | View MAPK14 Products |
| Validator | MAPK14 siRNA Set. For specific knockdown verification and functional phenotyping. | View MAPK14 Products |
| Related Target | MAPK11 (p38 Beta). Closest structural homolog essential for isoform selectivity counter-screening. | View MAPK11 Products |
| Related Target | MAPKAPK2 (MK2). Direct downstream substrate required for functional kinase inhibition readouts. | View MAPKAPK2 Products |
Critical Assay Challenges & TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (p38α vs β/γ/δ) | Homolog panel proteins (MAPK11, MAPK12, MAPK13) >95% purity, mass spectrometry verified |
| Resistance Mutation Profiling | MAPK14 T106M Gatekeeper mutant and DFG-out conformation mutants; Sequence Verified; High Purity |
| Activation State Dependence | Dual-phosphorylated (Thr180/Tyr182) Active Kinase vs Unphosphorylated Inactive forms available |
| Allosteric vs ATP-Competitive Binding | Unphosphorylated (inactive) and hyperphosphorylated (active) proteins with defined specific activity |
| Lack of Assay Controls | High-affinity phospho-specific and total benchmark antibodies included for normalization |
| False Positives in Cellular Screens | Sequence-verified siRNA sets for target-specific knockdown verification |
Live p38 Alpha R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for p38 Alpha (MAPK14) therapeutics is undergoing a structural renaissance as major drug developers pivot from early-generation systemic ATP-competitive kinase inhibitors—plagued by hepatotoxicity and transient efficacy due to upstream feedback loops—toward highly selective allosteric modulators and targeted protein degraders (PROTACs). Next-generation R&D leverages structural biology to exploit unique DFG-out conformations and tissue-specific delivery. Current clinical progression is increasingly centered on genetically defined rare diseases such as Facioscapulohumeral Muscular Dystrophy (FSHD) and neurodegenerative indications including synaptic dysfunction in early Alzheimer's disease.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Allosteric Small Molecule | Fulcrum Therapeutics, EIP Pharma (Neflamapimod) | FSHD, Neurodegeneration (AD) | Selectivity & Kinetic Assays (Need high-purity active/inactive kinase panels) |
| PROTAC / Degrader | Arvinas, Academic/Biotech Consortia | Refractory Oncology, Severe Inflammation | Ternary Complex Formation Assay (Need high-affinity recombinant protein & benchmark antibodies) |
| ATP-Competitive SMKI | Pfizer, Array BioPharma (Historical) | Severe Autoimmune, Cardiomyopathy | Enzymatic IC50 Profiling (Need native-folded active enzyme with low endotoxin) |
Conclusion
TarMart provides a comprehensive, high-purity reagent ecosystem for p38 Alpha drug discovery, including active/inactive kinases, mutant proteins, gene delivery, benchmark antibodies, and siRNA tools, enabling accurate isoform selectivity, resistance mutation profiling, and mechanism-of-action studies. Our products are rigorously sequence-verified and endotoxin-controlled (<1 EU/μg), ensuring reliable assay results for both academic and pharmaceutical research.